Objective: The aim of the study was to prospectively assess whether regular use of synthetic cannabinoids (SCs) affects the duration of opioid-related withdrawal and craving symptoms in patients undergoing drug detoxification treatments.
| INTRODUCTION
The widespread growth in popularity of novel psychoactive substances (NPSs) represents a significant threat for the global public health. By The NPSs (a) are increasingly used, whereas the use of international controlled drugs seems to have stabilized over the past decades (EMCDDA, 2016 Annual Report) ; (b) have worldwide diffusion via the Internet (Martinotti, Corazza, Achab, & Demetrovics, 2014); attract new users due to strong psychoactive effects and lack of detectability in routine urine tests (Schifano, Orsolini, Papanti, & Corkery, 2015) . Among the most common classes of NPSs, synthetic cannabinoids (SCs), synthetic cathinones, phenylethylamines, piperazines, and tryptamines are often detected. The use of SCs is associated with diverse clinical symptoms of acute, subacute, and chronic toxicity (Castaneto et al., 2014; Shalit et al., 2016) including the possibility of dependence and withdrawal syndrome (Nacca et al., 2013; Zimmermann et al., 2009 ). The history of other drug use plays a relevant role as a predictor of SCs consumption. According to the study of Bonar et al., patients of residential drug addiction treatment programs that reported lifetime use of SCs, in comparison to patients who did not use SCs, (a) were more likely to consume heroin, methadone, prescription opioids, prescription sedatives, amphetamines, ecstasy, cannabis, hallucinogens, inhalants, and tobacco and (b) had higher levels of depression, psychiatric distress, paranoid ideation, and psychoticism (Bonar, Ashrafioun, & Ilgen, 2014) . In this study, the use of SCs and traditional drugs in combination was determined by the motivation to avoid the routine urine test in the hospitals and to enhance the effects or treat withdrawal symptoms related to other substances (Bonar et al., 2014) . Among subjects with substance use disorders, individuals using SCs reportedly show lower age, lower educational level, lower number of hospitalizations, shorter duration of substance use, higher amount of legal problems, and more frequent relapses and dropouts in comparison to individuals not using SCs (Nurmedov, Yilmaz, Darcin, Noyan, & Dilbaz, 2015) .
Injection drug users who take SCs and/or other NPSs as substitutes of traditional drugs are considered a population at particularly elevated risk of developing adverse health effects related to synthetic drugs in comparison to subjects using only traditional injected drugs or NPSs (EMCDDA, 2013; Wagner et al., 2014) . Polydrug use represents an important concern for health care specialists as (a) it can increase health risks and harms (EMCDDA, 2013), (b) it can worsen treatment outcomes, and (c) it can create the so-called phenomenon of garbage head syndrome, that is, a very high level of alteration of consciousness and inhibition resulting from a random combination of more than one psychoactive substance (Iudici, Castelnuovo, & Faccio, 2015) . (Bonar et al., 2014; Nurmedov et al., 2015; Rodgman, Verrico, Worthy, & Lewis, 2014; Wagner et al., 2014) .
Despite these preliminary data, however, a clear picture of the cooccurrence of SCs and opioids use has not been presented in the literature, and there is a lack of studies assessing the role of SCs in longitudinally affecting the course of opioids-induced addiction-related symptoms. The aim of the present study was to prospectively assess whether the regular use of SCs worsens the duration of opioid withdrawal and craving symptoms in patients undergoing specific drug detoxification treatments.
| METHODS

| Study design
We conducted a prospective naturalistic case-control study between were not included in the study due to the use of opioids in combination with substances other than SCs (i.e., alcohol n = 43, sedative or hypnotics n = 52, cannabis n = 68, stimulants n = 35, and synthetic cathinones n = 6).
In addition to the diagnosis of opioid use disorder, the inclusion criteria for participants were (a) age of 18-45 years, (b) the last opioid intake 12-36 hr before the admission, (c) positive opioid urine test at the time of admission, (d) negative urine tests for other illicit drugs at the time of admission, (e) the absence of acute symptoms of somatic diseases (i.e., decompensated liver and cardiovascular disorders, HIV, and tuberculosis), and (f) availability of drug history data from the last year.
One of the two study groups (i.e., the SCs group) was made of 47 patients with the diagnosis of opioid use disorder who regularly used SCs. Regular SCs consumption was defined as no less than 3-4 times per month minimum for half of the year preceding the beginning of the study. The use of SCs (i.e., JWH-18 and JWH-73) in 6 months prior the beginning of the detoxification therapy was assessed through (a) repeated positive urine tests conducted by local psychiatrists and (b) patients' self-reports. These data were collected as part of the longitudinal surveillance of people with addiction disorders in Kazakhstan (which is based on at least monthly visits in which the physical conditions, the course and the severity of dependence, and the intake of psychoactive substances are monitored). The other group (i.e., the control group) was made of 146 patients with the diagnosis of opioid use disorder who did not use SCs. A 1:3 case-control ratio was used to increase the statistical power of the analyses. The two groups were matched in sex, age, ethnicity, current severity of opioid dependence, and grade of opioid withdrawal severity at baseline. The procedure of participants' enrollment is summarized in Figure 1 . The symptoms of opioid withdrawal and craving were assessed daily in a period of 20 days since admission.
| Assessments
A 42-item recording form was designed and used by the three investigators. The form is based on three domains of the Addiction Severity Index (UNODC, 2009), namely, (a) general demographic data, (b) history of drug consumption, and (c) physical conditions. The SCs intake history, the course of opioid withdrawal and craving symptoms, as well as the treatment information were assessed. The opioid use disorder was diagnosed in all cases according to criteria of DSM-V. For the opioid withdrawal assessment, the Clinical Opiate Withdrawal Scale (COWS) was used (Wesson & Ling, 2003) . We summarized the degree of opioid withdrawal symptoms in four levels, according to the COWS, namely, mild (5-12 points), moderate (13-24 points), moderately severe (25-36 points), and severe (more than 36 points). The absolute values of withdrawal scores were also taken into consideration. We assessed the changes in craving symptoms daily using a specific visual analogue scale (VAS). This instrument ranks the scores from 0 to 10 for intensity of craving and provides a reliable subjective symptom's assessment (Mottola, 1993) . The study baseline was defined as the moment between the admittance to detoxification units and the beginning of pharmacological therapies (1-1.5 hr). Clinical and sociodemographic data were measured at baseline. In the follow-up visits, the objective and subjective symptoms of the opioid-related withdrawal and craving symptoms were assessed. The severity of withdrawal and craving symptoms were assessed on Days 1, 5, 10, 15, and 20.
| Detoxification treatment
The design of the study had a naturalistic approach as it intended to assess the clinical symptoms during the standard therapy without any new experimental treatment or intervention. The opioid withdrawal symptoms were treated with α2-adrenergic agonist (clonidine 0.6-0.9 mg/die for about 7-10 days); anxiety and insomnia were treated with benzodiazepines (diazepam 30-50 mg/die for about 7 days) and antipsychotics (quetiapine 200 mg/die along all the intervention). After clinically significant improvements (e.g., reduction of pain, subjective improvement of somatic and psychiatric status, and a 12-point decrease in COWS scores), usually occurring after 7-9 days of treatment, patients started cognitive behavioral therapy in addition to pharmacotherapy.
| Use of opioids and SCs
For what concerns opioids, we assessed the duration of intake, the onset of withdrawal symptoms, the average duration of the withdrawal periods, the type of opioids (e.g., heroin, acetylated poppy, prescribed opioids, and dezomorphine; Zabransky, 2012) , the dosages, the routes of administration, and the combination with other drugs often used to reduce withdrawal symptoms (including codeine, tropicamide, phenazepam, zopiclone, and trihexyphenidyl; Bersani, Coviello, et al., 2015; .
For what concerns SCs, we assessed the history of intake, the street names of the substances, the ways of drug purchasing, the lifetime motives for their use, the dosages, the frequency and the routes of administration, the age of first use, and the time since the last intake.
| Statistical analysis
Data analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for Windows. All parameters are presented as mean ± standard deviation. Considering the nonparametric distribution of some variables, we used Friedman F test and Mann-Whitney U test to compare continuous variables and chi-square test (χ 2 ) to compare categorical variables at baseline. The duration of the withdrawal syndrome that was equated to statistical survival period was analyzed with KaplanMeier method (Goel, Khanna, & Kishore, 2010) from the baseline until the moment of cessation of clinician-rated opioid symptoms (COWS points ≤ 5 points) or reduction of craving symptoms (VAS ≤ 2 points;
McMillan & Gilmore- Thomas, 1996) . We defined the follow-up period as 20 days for both dependent variables. The differences in duration of withdrawal periods and craving between two groups were assessed using the log-rank test. The Cox analysis was conducted to explore 3 | RESULTS
| Participants sociodemographic characteristics
Forty-seven patients with regular SCs consumption and 146 controls were evaluated. Details on their demographic and clinical characteristics are given in Table 1 . The majority of participants were males, unemployed, single, and of Asian ethnicity; the age ranged between 18 and 38 years.
| Opioid use
The age of first opioid use ranged between 15 and 34 years and the duration of opioid consumption between 3 months and 12 years. Most of the participants used heroin intravenously. Patients of the two groups did not present significant differences in 30 days' prevalence of nonprescribed medication intake. Tropicamide was mostly used as an alternative to heroin, whereas phenazepam and zopiclone were mostly taken to mitigate opioid withdrawal symptoms, and trihexyphenidyl was mostly taken to potentiate the effects of opioid intoxication. Baseline measures showed similar levels of severity of opioid withdrawal symptoms, craving, and opioid dependence in the two groups. Although the total COWS score revealed no differences between the two groups, the resting heart rate was higher in the SCs group than in the control group (3.15 ± 1 points and 2.62 ± 1.06, respectively, p = .04). Anxiety or irritability was also more severe in 
| Detoxification treatment
Details on the detoxification treatment are given in Section 2.3, whereas the quantitative characteristics of the treatment are given in 
| Opioid withdrawal course
The primary objective of the study was to assess whether the regular use of SCs worsens the duration of opioid withdrawal and craving symptoms in patients undergoing a specific drug detoxification treatment. The opioid withdrawal duration in the two groups was calculated using the Kaplan-Meier method. We evaluated the opioid withdrawal changes according to the COWS and the VAS scores (Figure 2 ). The mean duration of the objective symptoms assessed by the COWS score was 14.66 ± 0.27 days in SCs group versus 12.21 ± 0.13 days in non-SCs group. The log-rank test confirmed the significant relationship between the duration withdrawal symptoms and SCs consumption (p < .01). Taking into consideration the differences in the baseline scores of resting pulse rate and anxiety or irritability, the duration of those symptoms was bivariately analyzed with Mann-Whitney U test. Due to tachycardia duration, the groups did not reveal the differences: 3.60 ± 1.09 days in the SC group versus 3.65 ± 0.87 days in the control group (p = .31). In contrast, the anxiety or irritability demonstrated longer retention in the SC group in comparison to the control group (14.21 ± 1.89 days and 11.38 ± 1.74 days correspondingly, p < .001).
The craving symptoms had a longer duration in SCs group (17.98 ± 0.33 days) than in the non-SCs group (14.97 ± 0.22 days). Table 3 .
| DISCUSSION
To the best of our knowledge, this is the first study assessing the Our study confirms the findings of previous reports that showed an association between SCs and opioids in clinical settings (Bonar et al., 2014; Nurmedov et al., 2015) and more severe drug dependence in case of polydrug use compared to the only use either opioids or SCs (Wagner et al., 2014) . Additionally, our findings indicate that certain characteristics of SCs use can increase risks of prolonged opioidrelated withdrawal and craving symptoms.
From a molecular perspective, there is a complex pharmacodynamic interplay between opioid and cannabinoid neurotransmission.
Both antagonistic and agonistic interactions between opioids and cannabinoids have been reported in animal (Maguire & France, 2016; Wakley & Craft, 2011) as well as in human studies (Haney, 2007) . The acute concomitant use of opioids and cannabinoids can lead to increase extracellular levels of endogenous opioids, facilitation of their signaling, and modulation of mu-opioid receptors; the chronic concomitant use of opioids and cannabinoids can increase the amount of endogenous opioids and can activate the noradrenergic pathways of locus coeruleus (Scavone, Mackie, & Van Bockstaele, 2010) . According to animal studies, the agonistic influence of cannabinoids supports the growth of antinociceptive tolerance as well as it attenuates and modulates morphine withdrawal syndrome (Gerak, Zanettini, Koek, & France, 2015 (Gerak & France, 2016) , which can contribute to explain our study finding of individuals using SCs as an alternative to opioids. The cross-tolerance of SCs and opioids can lead to coaddictive effects for both classes of substances (Gerak et al., 2015) . Taken together, the results of the present study suggest that the regular use of SCs influences the recovery from opioid use disorder and prolongs the duration of withdrawal and craving symptoms. Further studies are needed to (a) gain more accurate knowledge of opioid use disorder complicated by SCs use, (b) more accurately understand the clinical and molecular cross talks between these groups of substances, and (c) develop more specific detoxification therapies for the conditions of polydrug use.
